Bexsero® vaccine (1 dose at study month zero)

Phase 3

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Meningoccocal Disease

Clinical Trial

Last updated: 1/2/2026

Regulatory Approvals

EMA

1/13/2013

Bexsero

Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.

Developer

NVS

Novartis AG

Related Pipeline

Genital Herpes

Sickle Cell Disease (SCD)

Melanoma

Moderate to Severe Chronic Plaque-type Psoriasis

Atopic Dermatitis